(Q31876901)

4 July 2017

title

Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer (English)

1 reference

4 July 2017

0 references

1 reference

Ohe Y

1

1 reference

4 July 2017

Yamamoto S

2

1 reference

4 July 2017

Suzuki K

3

1 reference

4 July 2017

Hojo F

4

1 reference

4 July 2017

Kakinuma R

5

1 reference

4 July 2017

Matsumoto T

6

1 reference

4 July 2017

Ohmatsu H

7

1 reference

4 July 2017

Nishiwaki Y

8

1 reference

4 July 2017

publication date

1 January 2001

1 reference

European Journal of Cancer

4 July 2017

published in

1 reference

4 July 2017

volume

37

1 reference

4 July 2017

issue

1

1 reference

4 July 2017

page(s)

54-63

1 reference

Estimates of the worldwide incidence of eighteen major cancers in 1985.

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Chemotherapy of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Patients at risk of chemotherapy-associated toxicity in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Risk factors of pneumonitis following chemoradiotherapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900350-6

7 January 2021

10.1016/S0959-8049(00)00350-6

Identifiers

DOI

1 reference

4 July 2017

1 reference